A61K 45 - Medicinal preparations containing active ingredients not provided for in groups

Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
11/1999
11/11/1999	CA2328108A1 Use of neglected target tissue antigens in modulation of immune responses
11/11/1999	CA2327543A1 Method of treating bladder and lower urinary tract syndromes
11/11/1999	CA2327355A1 Human receptor molecules
11/11/1999	CA2327263A1 Human protease associated proteins
11/11/1999	CA2327259A1 Human transcriptional regulator molecules
11/10/1999	EP0955372A2 Method for screening substance inhibiting activation of NF-kappa B
11/10/1999	EP0955056A1 Recombinant colony stimulating factor-1 for treatment of fungal infection
11/10/1999	EP0954575A2 Cerebellum and embryo specific protein
11/10/1999	EP0954565A1 Adipogenic differentiation of human mesenchymal stem cells
11/10/1999	EP0954532A1 Novel human apoptosis regulator
11/10/1999	EP0954525A1 Novel compounds
11/10/1999	EP0954519A1 Alpha-9 integrin antagonists and anti-inflammatory compositions therof
11/10/1999	EP0954340A1 Targeted combination immunotherapy of cancer
11/10/1999	EP0954334A1 Use of macrophage migration inhibitory factor antagonists for anti-cancer therapy
11/10/1999	EP0954333A2 Soluble lymphotoxin-beta receptors, anti-lymphotoxin receptor antibodies, and anti-lymphotoxin ligand antibodies as therapeutic agents for the treatment of immunological diseases
11/10/1999	EP0954331A1 Novel compounds
11/10/1999	EP0954319A1 Treatment of osteoporosis and metabolic bone disorders with nitric oxide substrate and/or donors
11/10/1999	EP0954318A1 A nasal spray containing an intranasal steroid and an antihistamine
11/10/1999	EP0954314A1 Dosage forms and method for ameliorating male erectile dysfunction
11/10/1999	EP0954313A1 Method for treating tumors having high ldl requirements employing mtp inhibitors
11/10/1999	EP0954310A1 Synergistic composition comprising rapamycin and calcitriol
11/10/1999	EP0954309A1 Hiv and cancer treatment
11/10/1999	EP0954305A2 Use of carbonic anhydrase inhibitors for treating macular edema
11/10/1999	EP0954301A1 Methods for providing safe local anesthesia
11/10/1999	EP0954297A1 Use of bisphenolic compounds to treat type ii diabetes
11/10/1999	EP0954294A1 Use of h2-antagonists for the manufacture of a topical composition for the treatment of colds
11/10/1999	EP0954292A1 Pharmaceutical formulations with delayed drug release
11/10/1999	EP0954283A2 Formulation and method for treating neoplasms by inhalation
11/10/1999	EP0954278A1 Pharmaceutical compositions containing kukui nut oil
11/10/1999	EP0776208B1 2,3-dihydro-1-(2,2,2-trifluoroethyl)-2-oxo-5-phenyl-1h-1,4-benzodiazepines
11/10/1999	EP0654038B1 Controlled release pharmaceutical formulations of 3'-azido-3'-deoxythymidine and methods of use
11/10/1999	CN1234742A Improvements in or relating to diagnostic/therapeutic agents and improvement relating to same
11/10/1999	CN1234736A Preparation for transport of active substance across barriers
11/10/1999	CN1234735A Method for treating skin pigmentation
11/09/1999	US5981770 Method for the preparation of (+)-calanolide A and analogues thereof
11/09/1999	US5981717 Mammalian tolloid-like gene and protein
11/09/1999	US5981604 Materials and methods for inhibiting bacterial cell wall biosynthesis
11/09/1999	US5981601 Method for enhancing cellular bioenergy
11/09/1999	US5981594 Method of treatment for diabetic neuropathy
11/09/1999	US5981579 Use of nitrovasodilators for treatment of disease or stress conditions in a non-human mammal
11/09/1999	US5981563 Orally administering a rapidly dissolving tablet comprising phentolamine or its pharmaceutically acceptable salts
11/09/1999	US5981526 Synergistic treatment or prevention of migraine
11/09/1999	US5981499 Topically administering in dry form a troche or a powder consisting of a dry dosage of an antibiotic selected from penicillins, beta-lactam antibiotics, tetracyclines, aminoglycosides, cephalosporins, macrolides, vancomycin salts
11/09/1999	US5981494 Administering to the mammal a glycosidase inhibitor to inhibit the conversion of pro-toxin to toxin which causes maleria, endotoxic shock or septic shock in mammals
11/09/1999	US5981487 Method of inhibiting smooth muscle cell proliferation
11/09/1999	US5981470 Administering pharmaceutical agent selected from the group consisting of an angiotensin converting enzyme inhibitor, an angiotensin ii-receptor antagonist, a renin inhibitor, and an angiotensin ii-receptor expression inhibitor
11/09/1999	US5981220 Nucleotide sequences coding protein associated with skin differentiation; diagnostic assays for detecting bone and skin disorders; treatment of osteoporosis, bone fractures
11/09/1999	US5981195 Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors
11/09/1999	US5981168 Method and composition for modulating amyloidosis
11/09/1999	US5980946 Collagen formulations
11/09/1999	US5980925 A washing solution comprising an anchoring agent for improving the efficacy of a polar microbiocide agent on the skin; hand washes, wound cleansers, body washes, mouthwashes, surgical scrubs
11/09/1999	US5980914 Administering an amount of clioquinol with vitamin b12 effective to treat or delay the onset of parkinson's disease
11/09/1999	US5979447 Occlusive dressings
11/09/1999	CA2102321C Partial liquid breathing of fluorocarbons
11/09/1999	CA2065111C Ionically crosslinked carboxyl-containing polysaccharides for adhesion prevention
11/04/1999	WO1999055900A2 Gcp
11/04/1999	WO1999055868A2 Fizz proteins
11/04/1999	WO1999055867A1 Delayed rectifier potassium channel subunit
11/04/1999	WO1999055855A2 Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
11/04/1999	WO1999055854A2 Insulin-like growth factor ii antisense oligonucleotide sequences and methods of using same to modulate cell growth
11/04/1999	WO1999055845A1 Cellular and animal models for diseases associated with altered mitochondrial function
11/04/1999	WO1999055831A2 Adenoviral vectors for treating disease
11/04/1999	WO1999055735A1 G-csf receptor agonist antibodies and screening method therefor
11/04/1999	WO1999055734A1 A g-protein coupled 7tm receptor (axor-1)
11/04/1999	WO1999055733A1 Cloning of a novel 7tm receptor axor-2
11/04/1999	WO1999055729A1 STAPHYLOCOCCUS AUREUS pyrH POLYPEPTIDES AND POLYNUCLEOTIDES
11/04/1999	WO1999055372A1 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
11/04/1999	WO1999055367A1 INTERNALIZING ErbB2 ANTIBODIES
11/04/1999	WO1999055359A1 Compositions and methods for extending the action of clostridial neurotoxin
11/04/1999	WO1999055357A1 Method for the treatment of fertility disorders
11/04/1999	WO1999055356A1 A method of detecting drug-receptor and protein-protein interactions
11/04/1999	WO1999055344A1 Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies
11/04/1999	WO1999055343A1 Cnre binding factors and uses thereof
11/04/1999	WO1999055339A1 Adenosine a1 receptor antagonist containing composition and method for restoring diuretic and renal function
11/04/1999	WO1999055338A1 Treatment of depression and pharmaceutical preparations therefor
11/04/1999	WO1999055336A1 Riluzole and levodopa combinations for treating parkinson's disease
11/04/1999	WO1999055323A1 Use of nmda antagonists for treatment of irritable bowel syndrome
11/04/1999	WO1999055322A1 Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders
11/04/1999	WO1999055312A2 Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
11/04/1999	WO1999055308A1 Aqueous composition comprising active ingredients for the de-pigmentation of the skin
11/04/1999	WO1999047131A3 Combination of a gaba-a alpha 5 inverse agonist and an acetylcholinesterase inhibitor
11/04/1999	WO1999042090A3 Treating cancer
11/04/1999	WO1999037788A9 Diagnosis and treatment of aur1 and/or aur2 related disorders
11/04/1999	WO1999034004A3 Metastatic breast and colon cancer regulated genes
11/04/1999	WO1999033981A3 Human signal peptide-containing proteins
11/04/1999	WO1999019481A3 Mammalian genes involved in viral infection and tumor suppression
11/04/1999	WO1998027113A9 Melanocortin derivatives for specific binding of melanocortin receptor 3, 4 or 5
11/04/1999	CA2330391A1 Homogeneous pharmaceutical compositions comprising abacavir, lamivudine and zidovudine
11/04/1999	CA2329328A1 Use of nmda antagonists for treatment of irritable bowel syndrome
11/04/1999	CA2328165A1 Arsenic sulfide compounds and derivatives thereof for the treatment of malignancies
11/04/1999	CA2328111A1 Compositions and methods for extending the action of clostridial neurotoxin
11/04/1999	CA2326825A1 Insulin-like growth factor ii antisense oligonucleotide sequences and methods of using same to modulate cell growth
11/04/1999	CA2326824A1 Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth
11/04/1999	CA2326755A1 G-csf receptor agonist antibodies and screening method therefor
11/04/1999	CA2326377A1 Internalizing erbb2 antibodies
11/04/1999	CA2326233A1 Delayed rectifier potassium channel subunit
11/04/1999	CA2326001A1 Fizz proteins
11/04/1999	CA2324865A1 A method of detecting drug-receptor and protein-protein interactions
11/04/1999	CA2323235A1 Adenoviral vectors for treating disease
11/03/1999	EP0953637A2 Acetylcholine receptor

1 ... 1001 1002 1003 1004 1005 1006 1007 1008 1009 1010 1011 1012 1013 1014 1015 1016 1017 1018 1019 1020 1021 ... 1151